Navigation Links
Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008.
Date:4/9/2008

LONDON, April 9 /PRNewswire/ -- Chiltern, a leading global clinical research organization, is pleased to announce that it is a Platinum sponsor of the 17th Annual Partnerships with CRO's in Las Vegas, Nevada from April 14 to the 16. Chiltern's presence will be enhanced with presentations by some of its executive team and employees. Chiltern will be at exhibit booth 328.

Tuesday, April 15, 2008 at 2:45 pm -- Track: Relationship Management

Resource Relationship Management: Instilling Loyalty and Longevity in

Clinical Teams

Shelby Morgan, Project Manager

Wednesday, April 16, 2008 at 1:30 pm -- Track: Innovation in Clinical

Trial Execution

Using Feasibility Studies to Proactively Identify the Best Sites and

Predict Resource Requirements to Better Manage Cost, Patients and

Timelines

Panelist: Sharon Wyatt Moore, MD, MBA, MPH, Executive Director, Medical

Affairs and Global Head of Quality

Wednesday, April 16, 2008 at 1:30 pm -- Track: Optimizing outsourcing

Contracts, Budgets and Processes

Making the Most of Your Functional Service Provider (FSP) Relationships --

An Emerging Trend in Outsourcing

Terri Ellis, Director, Budgets and Proposals

Wednesday, April 16, 2008 at 3:00 pm -- Track: Optimizing outsourcing

Contracts, Budgets and Processes

Standardization: The Holy Grail?

Moderator: Mac McElroy, M. Ed., Executive Director, Business Development,

Americas

"Chiltern is proud to sponsor and present at this major industry event," said John Vann, Chiltern's Executive Vice President, Americas. "Several of our sponsors will be present and this venue gives us an opportunity to discuss their upcoming needs as well as update them about Chiltern's recent growth, starting with the acquisition of CTMS this past October and more recently our acquisition of Drug Development Services, now Chiltern (Early Phase) Ltd in the UK."

Email: About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1200 people with 20 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200

Carlsbad

CA 92011

USA

Tel: 1 (760) 707 5025

Fax: 1 (760) 707 5022

Email: Catherine.Lemercier@chiltern.com

Richard Baptista

Chiltern International Ltd.

171 Bath Road

Slough

Berkshire

SL1 4AA

UNITED KINGDOM

Tel: 44 (0) 1753 512 000

Fax: 44 (0) 1753 511 116

Email: Richard.Baptista@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Marco Romano, MD Joins Chiltern as Medical Director, Europe
2. Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
3. Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc.
4. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
5. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
6. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
7. Chiltern Wins Top Prize
8. TriWest Sponsors Congressional Medal of Honor Convention
9. Tennessee Faith Leaders Call on Reps. Gordon & Blackburn to Co-sponsor Legislation to Protect Kids from Tobacco
10. West Coast Bank Will Sponsor the Doernbecher Freestyle on September 22, 2007
11. PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Offering the ... with an oil many times purer and more potent than the market has seen ... of Gstaad, Switzerland, as well as a patented chromatography process for extraction, to produce ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... in hospitals, today announced it has completed a round of funding to accelerate ... and its partners. Black Granite Capital is a growth equity firm focused on ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... the ATA 2017 President’s Awards recipients, comprised of organizations and individuals who ... , The ATA 2017 President’s Awards recognize individuals and organizations on ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and CEO ... Enterprising Women magazine as one of its 2017 Enterprising Women of the Year, ... have demonstrated that they have fast-growth businesses, mentor or actively support other women ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Miami native ... as a dentist. , “I could have never imagined back in 1991 that this ... said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: